Cite
HARVARD Citation
Cogle, C. et al. (2020). Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. British journal of haematology. pp. e211-e213. [Online].